Literature DB >> 19523820

The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus.

Christopher McGuigan1, Plinio Perrone, Karolina Madela, Johan Neyts.   

Abstract

Beta-2'-C-methyl purines (1, 2) are known inhibitors of hepatitis C virus (HCV). We herein report the synthesis, biological and enzymatic evaluation of their 5'-phosphoramidate ProTides. Described herein are seven l-alanine phosphoramidate derivatives with variations to the amino acid ester. The 1-naphthyl phosphoramidate of beta-2'-methylguanosine containing the benzyl ester (20) was the most active at 0.12microM, an 84-fold of increase in activity compared to the parent nucleoside (2) with no increase of cytotoxicity. The carboxypeptidase mediated hydrolysis of several ProTides showed a predictive correlation with their activity versus HCV in replicon.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523820     DOI: 10.1016/j.bmcl.2009.05.122

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

Review 1.  Advances in nucleoside monophosphate prodrugs as anti-HCV agents.

Authors:  Drew R Bobeck; Raymond F Schinazi; Steven J Coats
Journal:  Antivir Ther       Date:  2010

2.  Antiviral efficacy upon administration of a HepDirect prodrug of 2'-C-methylcytidine to hepatitis C virus-infected chimpanzees.

Authors:  Steven S Carroll; Kenneth Koeplinger; Marissa Vavrek; Nanyan Rena Zhang; Laurence Handt; Malcolm MacCoss; David B Olsen; K Raja Reddy; Zhili Sun; Paul D van Poelje; James M Fujitaki; Serge H Boyer; David L Linemeyer; Scott J Hecker; Mark D Erion
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

3.  INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.

Authors:  John H Vernachio; Blair Bleiman; K Dawn Bryant; Stanley Chamberlain; Damound Hunley; Jeff Hutchins; Brenda Ames; Elena Gorovits; Babita Ganguly; Andrea Hall; Alexander Kolykhalov; Yule Liu; Jerry Muhammad; Nicholas Raja; C Robin Walters; Jin Wang; Karen Williams; Joseph M Patti; Geoffrey Henson; Karolina Madela; Mohamed Aljarah; Arnaud Gilles; Christopher McGuigan
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

Review 4.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

5.  Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection.

Authors:  Jong Hyun Cho; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  Tetrahedron       Date:  2011-07-29       Impact factor: 2.457

Review 6.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

7.  Anchimerically Activatable Antiviral ProTides.

Authors:  Aniekan Okon; Marcos Romário Matos de Souza; Rachit Shah; Raquel Amorim; Luciana Jesus da Costa; Carston R Wagner
Journal:  ACS Med Chem Lett       Date:  2017-08-14       Impact factor: 4.345

8.  Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.

Authors:  Shui Li; Yan Jia; Blake Jacobson; Joel McCauley; Robert Kratzke; Peter B Bitterman; Carston R Wagner
Journal:  Mol Pharm       Date:  2013-02-04       Impact factor: 4.939

Review 9.  Phosphoramidates and phosphonamidates (ProTides) with antiviral activity.

Authors:  Magdalena Slusarczyk; Michaela Serpi; Fabrizio Pertusati
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

Review 10.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Authors:  Mary K Yates; Katherine L Seley-Radtke
Journal:  Antiviral Res       Date:  2018-12-08       Impact factor: 10.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.